1 | 12214266 | Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. | Oncogene | 2002 Sep 12 |
21 |
2 | 12964069 | Lapatinib ditosylate GlaxoSmithKline. | IDrugs | 2003 Sep |
3 |
3 | 14633707 | Epidermal growth factor receptor autocrine signaling in RIE-1 cells transformed by the Ras oncogene enhances radiation resistance. | Cancer Res | 2003 Nov 15 |
5 |
4 | 14737100 | Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. | Oncogene | 2004 Jan 22 |
10 |
5 | 14751502 | Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. | Int J Radiat Oncol Biol Phys | 2004 Feb 1 |
9 |
6 | 14967461 | Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. | Int J Radiat Oncol Biol Phys | 2004 Mar 1 |
1 |
7 | 15163842 | Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. | Oncologist | 2004 |
4 |
8 | 15374980 | A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. | Cancer Res | 2004 Sep 15 |
15 |
9 | 15528979 | Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. | Invest New Drugs | 2005 Jan |
4 |
10 | 15665275 | The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. | Cancer Res | 2005 Jan 1 |
13 |
11 | 15684311 | Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. | J Clin Oncol | 2005 Apr 10 |
6 |
12 | 15755991 | Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. | Clin Cancer Res | 2005 Mar 1 |
12 |
13 | 15833875 | Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. | Cancer Res | 2005 Apr 15 |
9 |
14 | 15857287 | Small molecules with EGFR-TK inhibitor activity. | Curr Drug Targets | 2005 May |
2 |
15 | 15955900 | Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. | J Clin Oncol | 2005 Aug 10 |
3 |
16 | 16020981 | Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma. | Oncology | 2005 |
1 |
17 | 16091755 | Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. | Oncogene | 2005 Sep 15 |
12 |
18 | 16397255 | Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. | Cancer Res | 2006 Jan 1 |
6 |
19 | 16452222 | Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. | Cancer Res | 2006 Feb 1 |
16 |
20 | 16452223 | Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. | Cancer Res | 2006 Feb 1 |
7 |
21 | 16682622 | A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. | Proc Natl Acad Sci U S A | 2006 May 16 |
15 |
22 | 16843263 | HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. | Cancer Cell | 2006 Jul |
2 |
23 | 16894399 | Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. | Drugs Today (Barc) | 2006 Jul |
10 |
24 | 16934227 | Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. | Biochem Pharmacol | 2006 Oct 16 |
2 |
25 | 16940802 | Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis. | Anticancer Drugs | 2006 Sep |
1 |
26 | 17001557 | [Molecular diagnostic and targeted therapy--"Barking dogs are going to bite": presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006]. | Zentralbl Gynakol | 2006 Oct |
1 |
27 | 17060407 | Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. | Jpn J Clin Oncol | 2007 Jan |
3 |
28 | 17092403 | Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. | Clin Breast Cancer | 2006 Oct |
3 |
29 | 17110623 | Lapatinib: current status and future directions in breast cancer. | Oncologist | 2006 Nov-Dec |
2 |
30 | 17113234 | The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours. | Cancer Treat Rev | 2007 Feb |
2 |
31 | 17192538 | Lapatinib plus capecitabine for HER2-positive advanced breast cancer. | N Engl J Med | 2006 Dec 28 |
6 |
32 | 17203189 | Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. | Oncol Rep | 2007 Feb |
6 |
33 | 17208435 | Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). | Eur J Cancer | 2007 Feb |
2 |
34 | 17250463 | Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. | Expert Opin Biol Ther | 2007 Feb |
11 |
35 | 17283152 | Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. | Cancer Res | 2007 Feb 1 |
13 |
36 | 17308062 | Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. | Mol Cancer Ther | 2007 Feb |
18 |
37 | 17320695 | Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy. | Urology | 2007 Feb |
4 |
38 | 17341725 | Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials. | J Natl Cancer Inst | 2007 Mar 7 |
1 |
39 | 17350323 | Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy. | Oral Oncol | 2007 Sep |
2 |
40 | 17402790 | HER-2-positive breast cancer: hope beyond trastuzumab. | BioDrugs | 2007 |
2 |
41 | 17407594 | relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor. | Theor Biol Med Model | 2007 Apr 3 |
2 |
42 | 17485900 | Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? | Breast Cancer | 2007 |
5 |
43 | 17489737 | Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. | Expert Rev Mol Diagn | 2007 May |
3 |
44 | 17513611 | Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. | Mol Cancer Ther | 2007 May |
19 |
45 | 17545611 | Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. | Cancer Res | 2007 Jun 1 |
4 |
46 | 17547474 | HER2-positive breast cancer: current and future treatment strategies. | Drugs | 2007 |
2 |
47 | 17555368 | Her signaling in pancreatic cancer. | Expert Opin Biol Ther | 2007 Jun |
2 |
48 | 17591827 | Lapatinib in breast cancer. | Ann Oncol | 2007 Jun |
5 |
49 | 17593621 | EGFR and HER-2 antagonists in breast cancer. | Anticancer Res | 2007 May-Jun |
3 |
50 | 17635524 | Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. | Cell Prolif | 2007 Aug |
26 |